Table 1 Baseline tumor and patient characteristics in relation to CYP27A1 expression

Characteristic

N (%)

N (%)

N (%)

N (%)

510 (79.1)

135 (20.9)

588 (72.3)

225 (27.7)

Age at BC diagnosis

64.9 (60.1–71.1)^a

66.2 (60.4–73.5)^a

1.02 (0.99–1.05)

60.7 (52.4–67.8)^a

61.3 (52.3–69.2)^a

1.00 (0.98–1.01)

 Age at diagnosis < 55 yrs

53 (10)

10 (7.4)

ref

179 (30.4)

74 (32.9)

ref

 Age at diagnosis ≥ 55 yrs

457 (90)

125 (92.6)

0.94 (0.44–2.00)

409 (69.6)

151 (67.1)

0.84 (0.60–1.18)

 Positive

428 (89.7)

94 (78.3)

ref

545 (92.7)

166 (74.1)

ref

 Negative

49 (10.3)

26 (12.6)

2.52 (1.50–4.20)

43 (7.3)

58 (25.9)

4.75 (3.05–7.41)

 Positive

243 (56.4)

52 (47.3)

ref

445 (75.7)

135 (60.3)

ref

 Negative

188 (43.6)

58 (52.7)

1.81 (1.16–2.84)

143 (24.3)

89 (39.7)

2.17 (1.55–3.03)

 ≤ 20 mm

353 (69.6)

92 (68.1)

ref

446 (75.9)

150 (66.7)

ref

 > 20 mm

154 (30.4)

43 (31.9)

1.10 (0.73–1.70)

142 (24.1)

75 (33.3)

1.62 (1.15–2.27)

 Negative

304 (63.3)

90 (68.7)

ref

351 (59.8)

144 (64.3)

ref

 Positive

176 (36.7)

41 (31.3)

0.81 (0.54–1.23)

236 (40.2)

80 (35.7)

0.84 (0.61–1.16)

 I and II

369 (73.9)

82 (62.6)

ref

466 (79.3)

134 (59.6)

ref

 III

130 (26.1)

49 (37.4)

1.70 (1.13–2.60)

122 (20.7)

91 (40.4)

2.37 (1.69–3.32)

FFPE block storage time, yrs

15.0 (12.0–19.0)^a

13.0 (10.0–17.0)^a

0.93 (0.89–0.97)

10.0 (7.0–12.0)^a

8.0 (6.0–11.0)^a

0.87 (0.82–0.92)

 No

160 (34.3)

55 (44.4)

ref

214 (36.4)

78 (34.7)

ref

 Yes

307 (65.7)

69 (55.6)

0.65 (0.43–0.97)

374 (63.6)

147 (65.3)

1.06 (0.76–1.47)

 No

204 (40.6)

50 (37.9)

ref

158 (26.9)

84 (37.3)

ref

 Yes

298 (59.4)

82 (62.1)

0.93 (0.61–1.40)

429 (73.1)

140 (62.5)

0.62 (0.45–0.87)

 No

388 (82.9)

97 (78.9)

ref

457 (77.7)

149 (66.2)

ref

 Yes

80 (17.1)

26 (21.1)

1.23 (0.74–2.03)

131 (22.3)

76 (33.8)

1.51 (1.07–2.14)